Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveil...

Full description

Bibliographic Details
Main Authors: Jing Nie, Huina Wu, Lei Sun, Yanjiao Ding, Yepeng Luan, Jiyong Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Subjects:
fuzuloparib
niraparib
olaparib
cost-effectiveness
maintenance treatment
ovarian cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.987337/full

Similar Items

Similar Items